Skip to content

Study of the Hummingbird TTS™ Tympanostomy Tube System

Post-Market Surveillance Study of the Preceptis Medical, Inc. Hummingbird TTS™ Tympanostomy Tube System

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03503591
Enrollment
109
Registered
2018-04-20
Start date
2016-01-29
Completion date
2021-08-31
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Otitis Media

Keywords

tympanostomy, myringotomy, otitis media, ear tubes, ear infection

Brief summary

The objective of this study was continued commercial evaluation of the intraoperative safety and performance of the H-TTS for the placement of ventilation tubes in pediatric patients undergoing a tympanostomy procedure under moderate sedation and local anesthetic.

Detailed description

The study was a multi-site, prospective and retrospective, treatment-only post-market study of the H-TTS. The study was performed in a commercial environment. Patients were already have a scheduled tympanostomy procedure with the H-TTS under moderate sedation and local anesthetic.

Interventions

DEVICEHummingbird Tympanostomy Tube System

Insertion of a ventilation tube under sedation and local anesthetic

Sponsors

Preceptis Medical, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
6 Months to 5 Years
Healthy volunteers
No

Inclusion criteria

* Age 6 months through 5 years of age * Candidates for ventilation tube placement * H-TTS used under moderate sedation and local anesthetic

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Procedures Converted From Sedation to General AnesthesiaIntra-operativePercentage of procedures that require conversion from sedation to general anesthesia
Rate of Intra-operative Adverse EventsIntra-operativeRate of intra-operative adverse events that occur from the beginning to the end of the procedure
Rate of Adverse Events Through DischargeThrough discharge, estimated to be approximately 90 minutes post-procedureRate of adverse events that occur between the end of the procedure and discharge

Countries

United States

Participant flow

Participants by arm

ArmCount
Insertion of a Ventilation Tube Under Sedation and Local Anesthetic
Children 6 months through 5 years of age, who are candidates for placement of VT.
109
Total109

Baseline characteristics

CharacteristicInsertion of a Ventilation Tube Under Sedation and Local Anesthetic
Age, Continuous19 Months
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United States
109 participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 109
other
Total, other adverse events
0 / 109
serious
Total, serious adverse events
0 / 109

Outcome results

Primary

Percentage of Procedures Converted From Sedation to General Anesthesia

Percentage of procedures that require conversion from sedation to general anesthesia

Time frame: Intra-operative

ArmMeasureValue (NUMBER)
Insertion of a Ventilation Tube Under Sedation and Local AnestheticPercentage of Procedures Converted From Sedation to General Anesthesia12.8 percentage of procedures converted
Primary

Rate of Adverse Events Through Discharge

Rate of adverse events that occur between the end of the procedure and discharge

Time frame: Through discharge, estimated to be approximately 90 minutes post-procedure

ArmMeasureValue (NUMBER)
Insertion of a Ventilation Tube Under Sedation and Local AnestheticRate of Adverse Events Through Discharge0 percentage of AEs through discharge
Primary

Rate of Intra-operative Adverse Events

Rate of intra-operative adverse events that occur from the beginning to the end of the procedure

Time frame: Intra-operative

ArmMeasureValue (NUMBER)
Insertion of a Ventilation Tube Under Sedation and Local AnestheticRate of Intra-operative Adverse Events0 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026